Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON EVERY ORDER
Research Comparison

KGLOW vs Thymosin Alpha-1

KGLOW and Thymosin Alpha-1 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.

Shared research areas:Cellular Longevity
ClassFour-component dermal research blend — GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg (80 mg total)N-acetylated 28-residue thymic peptide
Molecular weightNot specified3108.3 g/mol
CAS numberNot assigned / not specifiedNot assigned / not specified
Purity spec≥98%≥99%
Research areasDermatological, Cellular LongevityImmune, Cellular Longevity
Primary diluentBacteriostatic water (0.9% benzyl alcohol)Bacteriostatic water (0.9% benzyl alcohol)
Working windowCommonly worked with for 2–3 weeks at 2–8 °C, set by the TB-500 and GHK-Cu components.Commonly worked with for 2-4 weeks at 2-8 °C.
Lead degradation routeCopper dissociation from the GHK-Cu component at acidic pH or on chelator contact — the dominant failure mode, and visible as the blue fading.Deamidation and aspartate isomerisation in this Asn/Asp-rich sequence — the most plausible slow route.
Freeze–thawAliquot on reconstitution; four components degrade on four independent schedules.Aliquot on first reconstitution; the disordered chain tolerates a freeze but repeated cycles concentrate solutes at the ice interface.
Light sensitivityProtect from light.No specific light requirement beyond normal practice.

How they actually differ

Comparing the two: KGLOW is four-component dermal research blend — ghk-cu 50 mg / bpc-157 10 mg / tb-500 10 mg / kpv 10 mg (80 mg total), while Thymosin Alpha-1 is n-acetylated 28-residue thymic peptide — different molecular classes with different handling consequences; their leading degradation routes differ (copper dissociation from the ghk-cu component at acidic ph or on chelator contact for KGLOW, deamidation and aspartate isomerisation in this asn/asp-rich sequence for Thymosin Alpha-1), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.

KGLOW — origin

KGLOW is GLOW with a fourth component added: KPV, a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. The other three amounts are unchanged — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg — with KPV at 10 mg bringing the vial to 80 mg. KPV is studied primarily for anti-inflammatory activity in preclinical models, notably retaining that property of the parent hormone without its pigmentation-related effects.

Thymosin Alpha-1 — origin

Thymosin Alpha-1 is an N-terminally acetylated 28-amino-acid peptide derived from prothymosin alpha and originally isolated from thymic tissue. It is one of the most-studied immune-modulating peptides, examined for a role in T-cell maturation and immune signalling; the clinical formulation is known as Zadaxin.

KGLOW research themes

Collagen and matrix synthesis (GHK-Cu)

The majority component, with the deepest dermal research literature.

Anti-inflammatory pathways (KPV)

The addition that distinguishes KGLOW — studied for anti-inflammatory activity derived from alpha-MSH without pigmentation effects.

Angiogenesis and cell migration (BPC-157, TB-500)

Two complementary tissue-repair mechanisms, unchanged from GLOW.

Four-pathway design

Adds an inflammation arm to the three repair-focused mechanisms in GLOW.

Thymosin Alpha-1 research themes

T-cell maturation

Studied for a role in the maturation and function of T-cells in immune research models.

Immune signalling

Examined around innate immune signalling pathways, including Toll-like-receptor involvement, in preclinical work.

Infection and adjuvant research

Investigated in models of immune response to infection and as a research adjuvant.

KGLOW handling

  • Never reconstitute in acidic diluent — copper dissociation from the GHK-Cu component is the primary risk.
  • Keep EDTA and other chelators out of any buffer used with KGLOW.
  • Treat colour as data: clear even blue is correct; pale or green is not.
  • Protect from light and minimise headspace exposure for the TB-500 component.
  • Scale diluent to the 80 mg fill — habitually adding 2 mL as though to a 10 mg vial gives a solution eight times more concentrated than intended.

Thymosin Alpha-1 handling

  • Reach room temperature before opening.
  • Swirl to dissolve; the disordered peptide clears quickly.
  • Label aliquots with reconstitution date and diluent.

Both third-party tested

Every Popular Peptides batch of KGLOW and Thymosin Alpha-1 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

Verify a batchPublished COAsHow we test

KGLOW reference

Full KGLOW reference KGLOW storage KGLOW reconstitution KGLOW calculatorKGLOW product details

Thymosin Alpha-1 reference

Full Thymosin Alpha-1 reference Thymosin Alpha-1 storage Thymosin Alpha-1 reconstitution Thymosin Alpha-1 calculatorThymosin Alpha-1 product details

Related comparisons

5-Amino-1MQ vs KGLOW5-Amino-1MQ vs Thymosin Alpha-1BPC-157 vs KGLOWDSIP vs KGLOWDSIP vs Thymosin Alpha-1Epitalon vs KGLOWEpitalon vs Thymosin Alpha-1GHK-Cu vs KGLOW

KGLOW and Thymosin Alpha-1 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.